Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
BERKELEY, Calif., March 07, 2016 -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the 28th Annual ROTH Conference in Laguna Niguel, CA on Monday, March 14, 2016, at 1:00 pm Pacific Time.
To access the live webcast and subsequent archived recording of this and the company’s other presentations, please visit Aduro's website at www.aduro.com.
About Aduro
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, this platform is being developed as a treatment for multiple indications, including pancreatic, lung and prostate cancers, mesothelioma and glioblastoma. Aduro's STING pathway activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.
Contact: Sylvia Wheeler SVP, Corporate Affairs 510 809 9264 Media Contact: Angela Bitting 925 202 6211 [email protected] Mike Beyer Sam Brown, Inc. 312 961 2502
